{"id":"W3098262983","doi":"10.1093/noajnl/vdaa124","title":"Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02","year":2020,"lang":"en","type":"article","venue":"Neuro-Oncology Advances","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen's University","funders":"National Cancer Institute; National Institutes of Health","keywords":"Sorafenib; Erlotinib; Medicine; Clinical endpoint; Oncology; Internal medicine; Pharmacokinetics; Pharmacology; Phases of clinical research; Tyrosine-kinase inhibitor; Clinical trial; Epidermal growth factor receptor; Hepatocellular carcinoma; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003395476,0.0002116232,0.001007465,0.0001366293,0.00005724915,0.000004393075,0.0001231461,0.0001172521,0.00003814314],"category_scores_gemma":[0.0009209429,0.0001517746,0.0001488018,0.0003391805,0.000176279,0.0001157481,0.00006377214,0.0002329254,0.000002733003],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004551315,"about_ca_system_score_gemma":0.0002316678,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000008651263,"about_ca_topic_score_gemma":0.0002122112,"domain_scores_codex":[0.9975672,0.0003361367,0.001047786,0.0005098573,0.0002995228,0.0002395492],"domain_scores_gemma":[0.9977884,0.0009993184,0.0006492655,0.0002079503,0.0002048466,0.0001502417],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6140222,0.1624478,0.02376965,0.0002234255,0.0004393312,0.0007490455,0.002585896,0.0001002661,0.003952155,0.0002930761,0.001089138,0.190328],"study_design_scores_gemma":[0.3500412,0.6100229,0.0008638604,0.00006940772,0.0004020348,0.00002724435,0.0009713051,0.0001216344,0.01397369,0.00007422956,0.02331015,0.0001222978],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9920934,0.0002311219,0.00001348574,0.002414243,0.000787488,0.004317043,0.00003626562,0.00003406932,0.00007284631],"genre_scores_gemma":[0.9983451,0.0001484536,0.0002503264,0.0003744078,0.0001910139,0.0006375432,0.00002474476,0.00002406231,0.000004339654],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4475751,"threshold_uncertainty_score":0.6189187,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09047700081868112,"score_gpt":0.4332743799697267,"score_spread":0.3427973791510456,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}